<DOC>
	<DOC>NCT00905307</DOC>
	<brief_summary>This will be a multicenter, randomized, double-blind, placebo-controlled study designed to assess the tolerability, safety, and efficacy of OPC-34712 (0.25 to 6.0 mg) for the treatment of adult subjects hospitalized with an acute relapse of schizophrenia. Aripiprazole (10 to 20 mg) is included as a positive control to confirm the assay sensitivity of the study. A total of approximately 563 subjects will be screened at an estimated 75 sites worldwide in order to obtain approximately 450 randomized subjects.</brief_summary>
	<brief_title>Study to Evaluate the Efficacy, Safety, and Tolerability of Oral OPC-34712 and Aripiprazole for Treatment of Acute Schizophrenia</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Aripiprazole</mesh_term>
	<criteria>1. Male or female subjects between 18 and 65 years of age, with a diagnosis of schizophrenia, as defined by DSMIVTR criteria 2. Subjects who have been recently hospitalized or who would benefit from hospitalization for an acute relapse of schizophrenia 3. Subjects experiencing an acute exacerbation of psychotic symptoms 1. Females who are breastfeeding and/or who have a positive pregnancy test result prior to receiving study drug 2. Subjects with a current DSMIVTR Axis I diagnosis of: Schizoaffective disorder MDD Bipolar disorder Delirium, dementia, amnestic or other cognitive disorder Borderline, paranoid, histrionic, schizotypal, schizoid or antisocial personality disorder 3. Subjects presenting with a first episode of schizophrenia 4. Other protocol specific inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Relapsed</keyword>
</DOC>